Initial findings from our Phase IIa study of BPL-003 for Treatment Resistant Depression show BPL-003 delivered a rapid and durable antidepressant effect and short treatment duration. Read the full press release here: beckleypsytech.com/posts/beckley-…

We're working with Clerkenwell Health on a Phase IIa study investigating BPL-003 (our novel synthetic formulation of 5-MeO-DMT) as a potential treatment for Alcohol Use Disorder. Read more about the study below:

Results from our Phase I study of BPL-003 in healthy volunteers have been published in the Journal of Psychopharmacology. Read more here: beckleypsytech.com/posts/phase-i-…

We’ve dosed the first patient in the second part of our Phase IIa study exploring BPL-003 for Treatment Resistant Depression (TRD) - this time evaluating the effects of the compound alongside SSRI antidepressants. Learn more here: beckleypsytech.com/posts/first-pa…

It's #MentalHealthAwareness Week in the UK, where 1/4 people experience a mental health problem each year. It's a reminder to check in on ourselves and those around us, and spotlight the great work orgs are doing to change the stigma and provide support for those in need.

Insightful interview with our Chief Scientific and Medical Officer, Dr. Rob Conley, in Pharmafile's Spring Issue. Discover how psychedelic medicines are revolutionising neurological treatments. 🔗magazine.pharmafile.com/collections/ph…

We’re going to #ICPR2024! Check out our sessions below: 🗓️ 6 June, 10:45: We'll be joining PsyPAN to discuss Best Practices for Patient-Centred Psychedelic Trials. 🗓️ 6 June, 11:50: Research Scientist Anya Ermakova's session on 'Mapping the 5-MeO-DMT experience'.

The first participant has been dosed in a new research study exploring the effects of BPL-003 on the human brain at Centre for Psychedelic Research. Learn more about the study here: beckleypsytech.com/posts/first-pa…

Investigators have dosed the first participant in a new study examining the neurophysiological effects of BPL-003. Beckley Psytech psychiatrictimes.com/view/first-par…

We’re live at #ICPR2024 today! 🗓️ At 10:45, we’ll be talking to PsyPAN about Best Practices for Patient-Centred Psychedelic Clinical Trials in The Griffiths Gallery. 🗓️ At 11:50, Anya Ermakova will be talking about 'Mapping the 5-MeO-DMT experience' on the Sabina Stage.

We launched a new Participant Impact Report and Peer Support Pilot Program and received the Silver Standard in OVID Health's 2024 #PatientPartnershipIndex. To learn more and get involved, click here: beckleypsytech.com/posts/beckley-…

📣 Exciting update on Beckley Psytech's Phase 1/2a trial of ELE-101 (IV psilocin) for major depression. Initial results from Phase 1 and first patients dosed in Phase 2a. Full press release: ir.atai.life/news-releases/…

Today we announced initial results from our Phase I study of ELE-101 and that the first patients have been dosed in our Phase IIa study of ELE-101 for Major Depressive Disorder, commonly known as depression. Read more here: beckleypsytech.com/posts/beckley-…

We’re excited to welcome Dr Robert Hershberg to our Board of Directors. Read more about his appointment here: beckleypsytech.com/posts/beckley-…

Psychedelic medicines and the treatment of neurological conditions rebrand.ly/070a09 Beckley Psytech #psychedelics #neurology #psychoactives pic.x.com/3mzcyrn8tg

Anya Ermakova from Beckley Psytech will be presenting at ICP 2024/33rd International Congress of Psychology today. She'll discuss her microphenomenology analysis of 5-MeO-DMT subjective experiences. Make sure to drop by if you're attending!

ICYMI: We launched a Patient Impact Report with PsyPAN which shares insights from patients who had experiences of psychedelic clinical trials and explored potential options that could improve the experience for future participants. Read it here: beckleypsytech.com/resources/pati…

We’re proud to be supporting the Centre for Psychedelic Research team to run the first ever study investigating the effects of BPL-003 - our novel, synthetic intranasal formulation of 5-MeO-DMT benzoate - on the human brain. Read more about the study here: beckleypsytech.com/posts/first-pa…

Co-Founders, Cosmo Feilding Mellen and Lady Amanda Feilding, chatted to The Standard earlier this year to discuss the heritage, work and future of Beckley Psytech. Check out the full interview here: standard.co.uk/lifestyle/well…

Results from our Phase I study of BPL-003 in healthy volunteers have now been published in Volume 38, Issue 8 of the Journal of Psychopharmacology, showing BPL-003 can produce a rapid onset and short duration of subjective effect. Find the full paper here: journals.sagepub.com/doi/10.1177/02…